chevron_leftBack
As of 20 June 2026, GlycoNex InCorp. has a market cap of $80.42M USD, ranking #27100 globally and #1532 in Taiwan.
It ranks #2433 in the Healthcare sector, and #471 in the Biotechnology industry.
Key Stats
Market Cap
$80.42MUSD
2.54B TWD
Enterprise Value
$73.43MUSD
2.32B TWD
Revenue (TTM)
$1.2MUSD
37.86M TWD
EBITDA (TTM)
-$6.78MUSD
-214.39M TWD
Net Income (TTM)
-$7.44MUSD
-235.23M TWD
PS Ratio
67.2
PB Ratio
2.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Mei-Chun Yang
open_in_new
Founded
2001
Website
glyconex.com.tw
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 2.1% | -1.3% | -5.2% | -18% | 2.2% | 30% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
4168
台灣醣聯生技醫藥股份有限公司
ISIN: TW0004168000
Shares Out.:
Shares Outstanding:
112.521M1
Shares Float:
109.478M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
24.00 TWD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About GlycoNex InCorp.
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company’s development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed antibody drug currently under the lead optimization stage; and GNX1021, a first-in-class antibody–drug conjugate currently under preclinical stage. It is also involved in the development of SPD (Denosumab), a humanized IgG2 antibody that is in phase 3 clinical trial for the treatment of osteoporosis and cancer bone metastases. The company was incorporated in 2001 and is based in New Taipei City, Taiwan.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TWSE: 6919
|
$5.46B
7K%
172.76B TWD
|
-
|
|
TWSE: 6949
|
$1.61B
2K%
50.93B TWD
|
-
|
|
TPEX: 6696
|
$1.08B
1K%
34.04B TWD
|
-
|
|
TWSE: 7827
|
$726.25M
803%
22.97B TWD
|
-
|
|
|
TPEX: 7827
|
$600.25M
646%
18.98B TWD
|
-
|
|
TPEX: 06891
|
$571.26M
610%
18.06B TWD
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
227K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
199K%
|
19.0
|
|
EBR: ARGX
|
$47.43B
59K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.23B
55K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.27B
52K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$41.88B
52K%
33.71B CHF
|
37.2
|
chevron_leftBack